Versant Capital Management’s Cytek Biosciences CTKB Stock Holding History

Versant Capital Management’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.28K	Sell	515 -2,220	-81%	-$9.48K	﹤0.01%	2547
2026 Q1	$12K	Buy	2,735 +2,300	+529%	+$10.9K	﹤0.01%	2060
2025 Q4	$2.2K	Hold	435	–	–	﹤0.01%	2440
2025 Q3	$1.51K	Buy	435 +284	+188%	+$1.07K	﹤0.01%	2455
2025 Q2	$513	Sell	151 -788	-84%	-$2.63K	﹤0.01%	2548
2025 Q1	$3.77K	Sell	939 -89	-9%	-$461	﹤0.01%	2126
2024 Q4	$6.67K	Hold	1,028	–	–	﹤0.01%	1613
2024 Q3	$5.7K	Buy	+1,028	New	+$5.83K	﹤0.01%	1259
2023 Q4	–	Sell	-286	Closed	-$1.58K	–	1945
2023 Q3	$1.58K	Buy	+286	New	+$2.29K	﹤0.01%	1385

Other funds holding CTKB

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

LSERS

Louisiana State Employees Retirement System Baton Rouge, Louisiana $5.7B AUM 35.76% 1-Year Est. Return

NAM

NorthCrest Asset Manangement Plymouth, Minnesota $3.89B AUM 40.33% 1-Year Est. Return

EFG

Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return

SOADOR

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Versant Capital Management's CTKB Position: Q2 2026 in Review

Versant Capital Management reduced its Cytek Biosciences (CTKB) stake by 81% in Q2 2026, selling an estimated $9.48K and leaving 515 shares worth $2.28K. The position accounts for ﹤0.01% of the portfolio, ranked #2547.

Versant Capital Management first reported a position in CTKB in Q3 2023 and has held it in 9 quarters since. The position peaked at $12K in Q1 2026. 14 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

Versant Capital Management held 515 shares of Cytek Biosciences worth $2.28K as of Q2 2026.
Versant Capital Management sold 2,220 Cytek Biosciences shares in Q2 2026, an estimated $9.48K.
Cytek Biosciences made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #2547 holding.
Versant Capital Management first reported a position in Cytek Biosciences in Q3 2023 and has held it in 9 quarters since.
Versant Capital Management's Cytek Biosciences position peaked at $12K in Q1 2026.
14 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.